Personalis Inc (PSNL)

Jun 3, 2025, 4:00 PM EDT - 2 days ago

Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

Jun 2, 2025, 4:00 PM EDT - 3 days ago

New Data Shows NeXT Personal® Identifies Breast Cancer Patients Receiving Neoadjuvant Therapy that are at High Risk for Relapse

May 22, 2025, 6:00 AM EDT - 15 days ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Assay for Residual Cancer and Recurrence Detection

May 14, 2025, 4:01 PM EDT - 22 days ago

Personalis to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 6, 2025, 8:41 PM EDT - 4 weeks ago

Personalis, Inc. (PSNL) Q1 2025 Earnings Call Transcript

May 6, 2025, 4:01 PM EDT - 4 weeks ago

Personalis Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:00 PM EDT - 5 weeks ago

Personalis' NeXT Personal® Detects 100% of Colorectal Cancer Relapses Ahead of Imaging in VICTORI Cancer Study

Apr 22, 2025, 4:01 PM EDT - 6 weeks ago

Personalis to Announce First Quarter 2025 Financial Results

Apr 22, 2025, 6:00 AM EDT - 6 weeks ago

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Mar 26, 2025, 4:01 PM EDT - 2 months ago

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Mar 3, 2025, 6:00 AM EST - 3 months ago

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Feb 27, 2025, 7:40 PM EST - 3 months ago

Personalis, Inc. (PSNL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:01 PM EST - 3 months ago

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 21, 2025, 4:21 PM EST - 3 months ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX GERN MRNA TEM

Feb 18, 2025, 4:01 PM EST - 3 months ago

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Feb 14, 2025, 10:50 AM EST - 3 months ago

Exciting Technology At Personalis, But Profitability Eludes Them

Feb 13, 2025, 4:01 PM EST - 4 months ago

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 28, 2025, 4:01 PM EST - 4 months ago

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 5:00 AM EST - 5 months ago

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Jan 7, 2025, 4:01 PM EST - 5 months ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

Dec 19, 2024, 9:00 AM EST - 6 months ago

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

Dec 16, 2024, 8:00 AM EST - 6 months ago

Personalis and Tempus Expand Collaboration to Biopharma

TEM

Nov 20, 2024, 4:01 PM EST - 7 months ago

Personalis to Participate at Upcoming Investor Conferences

Nov 6, 2024, 8:11 PM EST - 7 months ago

Personalis, Inc. (PSNL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:01 PM EST - 7 months ago

Personalis Reports Third Quarter 2024 Financial Results

Nov 5, 2024, 4:01 PM EST - 7 months ago

Personalis to Present at the Stifel 2024 Healthcare Conference

Oct 23, 2024, 4:01 PM EDT - 8 months ago

Personalis to Announce Third Quarter 2024 Financial Results

Sep 16, 2024, 9:00 AM EDT - 9 months ago

ESMO 2024 Data Expands on Compelling Performance of Personalis NeXT Personal® MRD Test

Aug 19, 2024, 4:05 PM EDT - 10 months ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 18, 2024, 7:47 AM EDT - 10 months ago

Personalis: Resetting My Strategy Following The Q2 Beat

Aug 16, 2024, 8:30 AM EDT - 10 months ago

Personalis and Tempus Announce Expanded Collaboration

TEM

Aug 7, 2024, 11:09 PM EDT - 10 months ago

Personalis, Inc. (PSNL) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:01 PM EDT - 10 months ago

Personalis Reports Second Quarter 2024 Financial Results

Jul 31, 2024, 4:01 PM EDT - 11 months ago

Personalis to Participate at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

Jul 24, 2024, 4:01 PM EDT - 11 months ago

Personalis to Announce Second Quarter 2024 Financial Results

Jun 18, 2024, 4:01 PM EDT - 1 year ago

Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference

Jun 13, 2024, 8:00 AM EDT - 1 year ago

Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call

Jun 4, 2024, 4:05 PM EDT - 1 year ago

ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring

May 31, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus

May 22, 2024, 9:05 AM EDT - 1 year ago

Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024

May 22, 2024, 9:00 AM EDT - 1 year ago

Antares Bolsters Private Wealth Team with Three New Senior Appointments

KHC

May 8, 2024, 11:53 PM EDT - 1 year ago

Personalis, Inc. (PSNL) Q1 2024 Earnings Call Transcript

May 8, 2024, 4:01 PM EDT - 1 year ago

Personalis Reports First Quarter 2024 Financial Results

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Personalis to Announce First Quarter 2024 Financial Results

Mar 28, 2024, 4:01 PM EDT - 1 year ago

Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 28, 2024, 9:00 AM EDT - 1 year ago

Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 26, 2024, 9:00 AM EDT - 1 year ago

Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring

Feb 28, 2024, 9:20 PM EST - 1 year ago

Personalis, Inc. (PSNL) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 4:01 PM EST - 1 year ago

Personalis Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 14, 2024, 4:01 PM EST - 1 year ago

Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results